A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: ACP-196
DRUG: Moxifloxacin 400 mg
DRUG: Placebo

Sponsor

Acerta Pharma BV